论文部分内容阅读
目的探讨美罗培南静脉注射联合吸入治疗呼吸机相关性肺炎患者的临床疗效。方法选取2014年5月至2015年5月河南省台前县人民医院收治的100例呼吸机相关性肺炎患者作为研究对象,按随机数字表法将其分为对照组(45例)和研究组(55例)。对照组患者静脉滴注美罗培南,研究组患者在对照组基础上给予美罗培南吸入治疗,比较两组患者治疗前后的白细胞计数(WBC)、动脉血氧分压(Pa O2)、临床疗效及不良反应发生情况。结果治疗后,研究组患者的WBC明显低于对照组,Pa O2明显高于对照组,差异均有统计学意义(均P<0.05);研究组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);研究组患者的不良反应发生率为14.5%(8/55),明显低于对照组的82.2%(37/45),差异有统计学意义(P<0.05)。结论美罗培南静脉注射联合吸入治疗呼吸机相关性肺炎患者临床疗效明显,对改善血液指标与不良反应发生具有积极作用。
Objective To investigate the clinical efficacy of Meropenem combined with intravenous inhalation in the treatment of patients with ventilator-associated pneumonia. Methods A total of 100 ventilator-associated pneumonia patients admitted to Taitian County People’s Hospital of Henan Province from May 2014 to May 2015 were selected as the research objects. According to the random number table method, they were divided into control group (45 cases) and study group (55 cases). The patients in the control group were given Meropenem intravenously. The patients in the study group were given inhalation of Meropenem on the basis of the control group. The WBC, Pa O2, before and after treatment were compared between the two groups. The clinical efficacy and adverse effects Reaction occurred. Results After treatment, the WBC in the study group was significantly lower than that in the control group, Pa O2 was significantly higher than the control group (all P <0.05); the total effective rate of treatment group was significantly higher than that of the control group, The difference was statistically significant (P <0.05). The incidence of adverse reactions in study group was 14.5% (8/55), which was significantly lower than that in control group (82.2%, 37/45) (P < 0.05). Conclusion Meropenem combined with intravenous inhalation in the treatment of patients with ventilator-associated pneumonia has obvious curative effect, which has a positive effect on improving blood parameters and adverse reactions.